What is MDWD's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 0.15B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for MDWD?

P/E (TTM) is n/a and 52-week range is $11.84 to $19.70 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s MDWD figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for MDWD?

The company profile lists revenue (TTM) near $12M, net income (TTM) near -$2.02B, EPS (TTM) near -$1.60 when available from the market-data feed. Figures are informational and may lag live markets.

Where is Mediwound Ltd based, and what identifiers does Chartloom list?

The company context section lists headquarters in Yavne, Central(HaMerkaz), IL, 12.9M shares outstanding, ISIN IL0011316309 when available from company profile and filing metadata.

Please enable JavaScript to continue using this application.

Mediwound Ltd

$MDWD

Health Care · Pharmaceuticals

IR Run Scenarios

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

MediWound Ltd. is a biopharmaceutical company, which engages in the development, manufacture, and commercialization of products to address needs in the fields of severe burns, chronic wounds, and other hard-to-heal wounds. The company is headquartered in Yavne, Central(Hamerkaz) and currently employs 121 full-time employees. The company went IPO on 2014-03-20. Company's portfolio is focused on next-generation protein-based therapies for burn and wound care and tissue repair and includes products such as, NexoBrid, a concentrate of proteolytic enzymes enriched in bromelain, which is an easy to use, topically-applied product that removes eschar in four hours without harming the surrounding healthy tissues. ; EscharEx biological drug candidate for the debridement of chronic and other hard-to-heal wounds; MW005 a topically applied biological drug candidate for the treatment of non-melanoma skin cancers, based on the same API of NexoBrid and EscharEx products, a concentrate of proteolytic enzymes enriched in bromelain.

Employees

121

Website

www.mediwound.com/

IPO

2014-03-20

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)